SCN9A Loss of Function Mutations E1679 ACKNOWLEDGMENTS The authors wish to thank the patients and their families for kindly participating in this study. Contract grant sponsor: This work was made possible by grants from St John’s College in Cambridge, the Wellcome Trust, Pfizer, and the National Institute of Biotechnology in the Negev. REFERENCES Ahmad S, Dahllund L, Eriksson AB, Hellgren D, Karlsson U, Lund PE, Meijer IA, Meury L, Mills T, Moody A, Morinville A, Morten J, O’Donnell D, Raynoschek C, Salter H, Rouleau GA, Krupp JJ. 2007. A stop codon mutation in SCN9A causes lack of pain sensation. Hum Mol Genet 16:2114-21. Baroudi G, Pouliot V, Denjoy I, Guicheney P, Shrier A, Chahine M. 2001. Novel mechanism for Brugada syndrome: defective surface localization of an SCN5A mutant (R1432G). Circ Res 88:E78-83. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, Gribble FM, Woods CG. 2006. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444:894-8. Cummins TR, Dib-Hajj SD, Waxman SG. 2004. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci 24:8232-6. Drenth JP, Waxman SG. 2007. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest 117:3603-9. Estacion M, Dib-Hajj SD, Benke PJ, Te Morsche RH, Eastman EM, Macala LJ, Drenth JP, Waxman SG. 2008. NaV1.7 gain- of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci 28:11079-88. Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, Ostman J, Klugbauer N, Wood JN, Gardiner RM, Rees M. 2006. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52:767-74. Gelfand Y, Rodriguez A, Benson G. 2007. TRDB--the Tandem Repeats Database. Nucleic Acids Res 35(Database issue):D80- 7. Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M, Fraser R, Young C, Hossain S, Pape T, Payne B, Radomski C, Donaldson G, Ives E, Cox J, Younghusband HB, Green R, Duff A, Boltshauser E, Grinspan GA, Dimon JH, Sibley BG, Andria G, Toscano E, Kerdraon J, Bowsher D, Pimstone SN, Samuels ME, Sherrington R, Hayden MR. 2007. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet 71:311-9. Herzog RI, Cummins TR, Ghassemi F, Dib-Hajj SD, Waxman SG. 2003. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J Physiol 551:741-50. Klugbauer N, Lacinova L, Flockerzi V, Hofmann F. 1995. Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. Embo J 14:1084-90. Liu K, Yang T, Viswanathan PC, Roden DM. 2005. New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation 112:3239-46. Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, Schulze-Bahr E, Fukuhara S, Mochizuki N, Makiyama T, Itoh H, Christiansen M, McKeown P, Miyamoto K, Kamakura S, Tsutsui H, Schwartz PJ, George AL Jr, Roden DM. 2008. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest 118:2219-29. Marban E, Yamagishi T, Tomaselli GF. 1998. Structure and function of voltage-gated sodium channels. J Physiol 508:647-57. Nilsen KB, Nicholas AK, Woods CG, Mellgren SI, Nebuchennykh M, Aasly J. 2009. Two novel SCN9A mutations causing insensitivity to pain. Pain 143:155-8.